Immune responses to COVID ‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma: results from the Myeloma UK ( MUK) nine OPTIMUM trial
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18714 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Sian E Faustini und 14 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. Hauptthemen laut MEDLINE: COVID-19, Multiple Myeloma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cancer Research UK, MRF_, Myeloma UK.
Abstract (Originalsprache)
Multiple myeloma (MM) and anti‐MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID‐19) and other infections. We investigated anti‐severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) antibodies longitudinally in ultra‐high‐risk patients with MM receiving risk‐adapted, intensive anti‐CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross‐reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID‐19, even with intensive anti‐CD38 therapy for high‐risk MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Immunology Service, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
- Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, UK.
- Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK.
- Protective Immunity from T cells to COVID-19 in Health workers, Oxford, UK.
- Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
- The Leeds Teaching Hospitals NHS Trust, Leeds, UK.
ORCID-Profile: Sarah Brown, Guy Pratt, Gordon Cook, Martin F Kaiser, Jennifer L J Heaney
Förderung
- Cancer Research UK
- MRF_
- Myeloma UK
- University of Leeds
Zitieren
APA
Faustini, S. E., Hall, A., Brown, S., Roberts, S., Hill, H., Stamataki, Z., (PITCH) consortium, Jenner, M. W., Owen, R. G., Pratt, G., Cook, G., Richter, A., Drayson, M. T., Kaiser, M. F., & Heaney, J. L. J. (2023). Immune responses to COVID ‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma: results from the Myeloma UK ( MUK) nine OPTIMUM trial. British Journal of Haematology. https://doi.org/10.1111/bjh.18714
Vancouver
Faustini SE, Hall A, Brown S, Roberts S, Hill H, Stamataki Z, et al. Immune responses to COVID ‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma: results from the Myeloma UK ( MUK) nine OPTIMUM trial. British Journal of Haematology. 2023. doi:10.1111/bjh.18714
BibTeX
@article{Faustini2023,
author = {Faustini, Sian E and Hall, Andrew and Brown, Sarah and Roberts, Sadie and Hill, Harriet and Stamataki, Zania and (PITCH) consortium, (PITCH) consortium and Jenner, Matthew W and Owen, Roger G and Pratt, Guy and Cook, Gordon and Richter, Alex and Drayson, Mark T and Kaiser, Martin F and Heaney, Jennifer L J},
title = {Immune responses to COVID ‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma: results from the Myeloma UK ( MUK) nine OPTIMUM trial},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18714}
}
EUVIMED